CCO Infectious Disease Podcast

Key Decisions in HIV Care: Choosing ART in the Context of Virologic Failure and Resistance

Episode Summary

In this on-demand recording of a live webinar, expert faculty review key considerations when choosing ART for patients with virologic failure and resistance, including how to build an optimized background regimen and the data to support the inclusion of novel therapies into ART regimens.

Episode Notes

In this episode from the series “Key Decisions in HIV Care,” W. David Hardy, MD, and Josep M. Llibre, MD, PhD, discuss important considerations for ART use in the context of virologic failure and resistance, including:

A discussion of the definitions of the following: highly treatment experienced, complex ART, multidrug-resistant HIV, and limited treatment options
The scope of the problem, including data from the CNICS cohort
DHHS and EACS guideline recommendations on the management of virologic failure and drug resistance, including recommendations for the use of genotypic and phenotypic genotyping and proviral DNA sequencing
Construction of an optimized background regimen with discussion of the OPTIONS, DAWNING, NADIA, and VIKING-3 trials
Novel treatment options, including ibalizumab and data from TMB-301/-311, fostemsavir and data from BRIGHTE, and lenacapavir and data from CAPELLA

Presenters:

W. David Hardy, MD
Scientific and Medical Consultant
Adjunct Clinical Professor of Medicine
Division of Infectious Diseases
Keck School of Medicine of USC
Los Angeles, California

Josep M. Llibre, MD, PhD
Senior Consultant Physician and Clinical Researcher
Infectious Disease and “Fight against AIDS and Infectious Diseases Foundation”
Hospital Universitari Germans Trias i Pujol
Badalona
Barcelona, Spain

Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.

Follow along with the slides at:
https://bit.ly/3z9AtL0

Link to full program:
https://bit.ly/2TXTYWx